Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Insider Monkey on MSN5d
Is Teva Pharmaceutical (TEVA) Trading at a Discount?Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Pharmaceutical Technology on MSN23h
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback